Tegopen

(Cloxacillin)

PreclinicalSmall molecule

Bristol-Myers Squibb

Tegopen is one of 10 small molecule programs targeting Dialysis Patients. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Dialysis PatientsCompleted

Dialysis PatientsPreclinical

Completed

Competition

Competitive Landscape

13 competitors in Dialysis Patients

#DrugCompanyPhaseTrials

Betadine

BBecton, Dickinson and Company

Approved

1 2

Sodium Valproate

AstraZeneca

Phase 3

2 3

Evrenzo

Astellas

Phase 2

2 4

KN060

SSuzhou Alphamab Co., Ltd.

Phase 2

1 5

Tirosint

IInstitut Jerome Lejeune

Preclinical

1 6

Deca-Durabolin

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Triferic

RRockwell Medical Technologies, Inc.

Preclinical

3 9

Tegopen

Bristol-Myers Squibb

Preclinical

1 10

Colecalciferol

UUniversity of Turku

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Post-ApprovalRecruiting

MPA

NCT06726395

Q4 2028

ApprovedRecruiting

Surgical Wound Infection

NCT07896239

Clinical

Trials by Indication[1]

Staphylococcus Aureus Bacteremia2 trials

Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT03248063·315 enrolled

Staphylococcus Aureus Bacteremia Antibiotic Treatment Options

Completed·HHeinrich-Heine University, Duesseldorf·Phase 3·NCT01792804·215 enrolled

Bacteremia1 trial

Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.

Terminated·FFundación Pública Andaluza Progreso y Salud·Phase 3·NCT01875263·1 enrolled

MPA1 trial

Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia

Recruiting·RRegion Skane·Phase 4·NCT06726395·420 enrolled

Dialysis Patients1 trial

Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients

Completed·SShiraz University of Medical Sciences·N/A·NCT00885300·100 enrolled

Surgical Wound Infection1 trial

Antibiotic Penetration and Tissue Response in Infection and Reconstructive Surgery of the Head and Neck Region: A Microdialysis Study of Cefuroxime, Cloxacillin, Dicloxacillin, and Amoxicillin/Clavulanic Acid

Recruiting·TTejs Ehlers Klug·Approved·NCT07896239·16 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

TEGOPEN

NDA NDA050192

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Cloxacillin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cloxacillin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cloxacillin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA050192). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bristol-Myers Squibb

Tegopen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Trials by Indication[1]

Staphylococcus Aureus Bacteremia2 trials

Bacteremia1 trial

MPA1 trial

Dialysis Patients1 trial

Surgical Wound Infection1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News